Extended Data Fig. 1: Effect of actin concentration on inhibition by myosin inhibitors.
From: Aficamten is a small-molecule cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy
Inhibition of the actin-activated ATPase activity of bovine cardiac myosin S1 (0.2 µM) by (A) aficamten, (B) mavacamten, and (C) blebbistatin. Data shown are mean values ± SD (n = 4 technical replicates). Data are fit with four-parameter dose–response curves (1) with top values fixed at 1. Control ATPase activities: 0.115 µM/sec (5 µM actin), 0.258 µM/sec (15 µM actin), 0.443 µM/sec (45 µM actin). Results of curve fitting are shown in Table S1.
